Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL18130875 | 1.00 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL20400343 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL120390 | 0.94 | CA4 (0.52) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL11903451 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL1655126 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL11903448 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL7635443 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL21054602 | 0.94 | CA4 (0.52) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL22401093 | 0.94 | CA4 (0.52) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL161238 | 0.94 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090463-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | AVALYN PHARMA INC. | 2025-03-20 | — | — | US | disclosed |
| EP-3027026-B1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC (US) | 2024-11-13 | — | — | EP | disclosed |
| US-11980689-B2 | Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH) | AVALYN PHARMA INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20220087937-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2022-03-24 | — | — | US | disclosed |
| US-20210093570-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | AVALYN PHARMA INC. | 2021-04-01 | — | — | US | disclosed |
| US-20210093569-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | AVALYN PHARMA INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3782604-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | Windward Pharma, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3027026-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | Windward Pharma, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150044288-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2015017728-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | WINDWARD PHARMA, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093569-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | ALK, JAK1, PAH | CA4 1016/4885CTSL 4751/4885CPT2 4221/4885 |
| US-20150044288-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | ALK, JAK1, ABL1 | CA4 1930/4885CTSL 4654/4885CPT2 4558/4885 |
| US-20250090463-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | ALK, JAK1, PAH | CA4 1016/4885CTSL 4751/4885CPT2 4221/4885 |
| US-20210093570-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | ALK, JAK1, PAH | CA4 1016/4885CTSL 4751/4885CPT2 4221/4885 |
| US-20220087937-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | ALK, JAK1, ABL1 | CA4 1930/4885CTSL 4654/4885CPT2 4558/4885 |
| US-11980689-B2 | Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH) | ALK, JAK1, PAH | CA4 1016/4885CTSL 4751/4885CPT2 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.